343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). (September 2015) - Michalarea, V.; Lopez, J.; Lorente, D.; Carreira, S.; Hassam, H.; Parmar, M.; Turner, A.; Hall, E.; Fandos, S. Serrano; Decordova, S.; Swales, K.; Ruddle, R.; et al.